Table 1.
Comparison of the EC50 values of anandamide in the presence of the CB1 and CB2 receptor antagonists SR141716A and SR144528 and with methanandamide
| EC50 (μM) (95% CI) | 10 (μM) | 15 (μM) | 30 (μM) | 50 (μM) | 100 (μM) | |
|---|---|---|---|---|---|---|
| Anandamide | ||||||
| Control | 8.4 (7.3–9.7) | 0.22±0.01 | 0.33±0.03 | 0.31±0.03 | 0.32±0.02 | 0.34±0.01 |
| +SR141716A (1 μM) | 7.3 (4.6–11.7) | 0.26±0.02* | 0.31±0.03 | 0.34±0.04 | 0.33±0.04 | 0.27±0.02* |
| +SR144528 (1 μM) | ND | 0.02±0.004* | 0.10±0.03* | 0.08±0.02* | 0.17±0.01* | 0.16±0.007* |
| Methanandamide | ||||||
| 15.6 (14–17.4) | 0.05±0.04* | 0.13±0.01* | 0.25±0.03 | 0.26±0.04 | 0.26±0.04 | |
EC50 values represent the mean (95% confidential interval, CI). Other values represent the means±s.e.m. of the maximal peak Ca2+ elevation (Δmax ratio (F340/F380) in response to the agonist concentration indicated.
*
P<0.05 vs anandamide; ND, not determined.